急性冠脉综合征部分特殊人群抗血小板治疗研究进展  

Research progress on antiplatelet therapy in special populations of acute coronary syndrome

作　　者：李亮[1] 王梅[1] Li Liang;Wang Mei(Department of Cardiology,The Second Hospital of Hebei Medical University,Shijiazhuang 050000,China)

机构地区：[1]河北医科大学第二医院心血管内科东院区心内一科,河北石家庄050000

出　　处：《临床荟萃》2018年第9期767-770,共4页Clinical Focus

摘　　要：抗血小板治疗是急性冠脉综合征(acute coronary syndrome,ACS)患者治疗的基石,而阿司匹林联合一种P2Y12受体抑制剂是目前指南的I类推荐。抗血小板治疗在降低ACS患者心血管主要不良事件的同时,也增加了其出血风险。因此,对于部分特殊人群如高龄、合并糖尿病、卒中/短暂性脑缺血发作(TIA)及接受溶栓的ST段抬高型心肌梗死(STEMI)患者,在评估缺血风险与出血风险的同时,其抗血小板治疗的方案呈现着巨大的个体差异,本文就目前部分特殊人群的抗血小板治疗的研究进展进行综述。Antiplatelet therapy is the cornerstone of the treatment for patients with acute coronary syndrome （ACS）, and aspirin combined with a P2Y12 reccptor inhibitor is currently the I recommendation in the guidelines. Antiplatelet therapy increases the risk of bleeding while reducing major cardiovascular adverse events in ACS patients. Therefore, for some special populations such as advanced age, diabetes, stroke/TIA, and STEMI patients receiving thrombolysis, the antiplatclct therapy regimen and duration are presenting huge individual differences while evaluating the ischemia risk and bleeding risk. This article reviews the current research progress of antil？latelet therapy in these special populations.

关 键 词：急性冠状动脉综合征 抗凝药 心肌梗死 老年人 

分 类 号：R542.2[医药卫生—心血管疾病]